B efore the immune system can attack an invading pathogen, it must identify the intruder. Breakthroughs in understanding this process have garnered three scientists this year's Nobel Prize in Physiology or Medicine, which was announced on 3 October in Stockholm.
But the award was quickly overshadowed by sadness when it emerged that the winner of half the 10-million-Swedish-krona (US$1.5-million) prize, Ralph Steinman of the Rockefeller University in New York, had died on 30 September. Although Nobel prizes are not awarded posthumously, the Nobel committee was not aware of Steinman's death when it reached its decision. The committee has since confirmed that the award still stands. Ironically, Steinman was being treated for his pancreatic cancer with a therapy derived from his original discovery.
Together, his work and that of the other two winners -Jules Hoffmann at the French National Centre for Scientific Research (CNRS) Institute of Cell and Molecular Biology in Strasbourg and Bruce Beutler of the Scripps Research Institute in La Jolla, California -help to describe how two separate arms of the immune system work. Steinman discovered a type of immune cell, known as a dendritic cell, that is vital to the 'adaptive' immune system, which works out exactly which pathogen has invaded the body in order to trigger a targeted response. Hoffmann and Beutler earned their share of the prize for discovering a key to a more immediate line of defence, the 'innate' immune system, which identifies a foreign body as a potential pathogen. They identified the molecular sentinels that first sound the alarm by recognizing features shared by numerous pathogens.
Steinman's efforts to understand the immune system began in the early 1970s, when he joined the laboratory of Zanvil Cohn at Rockefeller as a postdoc. Cohn's group was studying an immune cell called the macrophage, which engulfs pathogens and other debris. Most researchers thought that macrophages then alerted adaptive immune cells called T cells to the presence of a specific pathogen. Once activated, T cells multiply and combat infection, either by killing pathogeninfected cells or by steering another type of immune cell, the B cell, to produce pathogenblocking antibodies.
In Cohn's lab, Steinman identified another type of immune cell, which he named the dendritic cell because of its long, tree-like arms 1 . Cohn and Steinman showed that these cells are much more important than macrophages in activating T cells.
At first, dendritic cells "were a minor cell and everybody was loath to accept them", recalls Siamon Gordon, an immunologist at 
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having two Popes -it was the dendritic cells versus the macrophages. " Steinman continued doggedly collecting data, and eventually won over his critics.
Two decades after the discovery of dendritic cells' crucial role, a team led by Hoffmann was investigating why fruitflies, which lack an adaptive immune system, don't succumb to fungal infection. In 1996, they reported that the Toll gene, previously linked to embryo development, was also important for battling infections 2 . Flies with mutations in Toll died when exposed to bacteria or fungi.
At around the same time, a team led by Beutler, then at the University of Texas Southwestern Medical Center in Dallas, had spent six years looking for an immune-system gene in mice that produces a protein to recognize lipopolysaccharide (LPS), a molecule produced by certain bacteria that can cause septic shock. "We were obsessed, " says Alexander Poltorak, an immunologist now at Tufts University in Boston, Massachusetts, who worked on the project. "We always thought we would find the gene tomorrow. "
The team eventually found its LPSsensing gene, and it looked remarkably like Hoffmann's Toll Meanwhile, Provenge (made by the biotechnology company Dendreon of Seattle, Washington), the only cellular immune therapy against cancer to be approved by the US Food and Drug Administration, exploits dendritic cells that recognize a molecule produced by prostate tumours. Culturing and reinjecting the cells back into the patient fortifies the immune response against the tumour.
"The reason why the field has progressed so much and is now in the clinic is because we understand how to activate the immune system, " says Cerundolo. ■ "I feel kind of weak in the knees, " Schmidt told reporters in Sweden via telephone. "It sort of feels like when my children were born. "
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All three scientists reached their conclusions on the basis of measurements of distant Type Ia supernovae. These occur in very specific types of binary star system, in which a white dwarf star tears matter away from its partner until it gains enough mass to explode. At their peak, Type Ia supernovae always emit roughly the same amount of light, making them useful as 'standard candles' by which to measure vast distances across the cosmos.
In the late 1980s and early 1990s, the prizewinners precisely measured the brightness of these supernovae using newly developed digital sensors. They then compared the brightness to the redshift -the change in colour of the light that results from the motion of the supernovae away from us. Both teams found that the supernovae were dimmer than expected at the measured redshift. The inescapable conclusion was that the Universe was not only expanding -which astronomers first realized in the 1920s -but expanding faster and faster.
Schmidt says that the finding was initially "pretty perplexing". Most astronomers had expected that the Universe's rapid growth following the Big Bang would gradually slow down as gravity pulled distant galaxies towards each other. Yet the discovery was accepted almost immediately by the astronomical community -in part because the idea of a cosmic pressure pushing the Universe outwards had already been mooted by Albert Einstein.
When Einstein applied his general theory of relativity to the Universe as a whole in 1917, his equations included a 'cosmological constant' which described just such an outward force. Over the past decade, observations of the largescale structure of the Universe, together with the cosmic microwave background radiation -the faint afterglow of the Big Bang -have also indicated that the majority of the Universe's energy remains undetected. Today, the astronomical community accepts that about 73% of the Universe's energy is invested in this cosmic acceleration. Known as dark energy, it remains a largely mysterious force. "Nobody really knows what it is that has been discovered, " says Peter Coles, an astrophysicist at Cardiff University, UK.
The predominant view is that dark energy results from quantum fluctuations in the vacuum of space, but efforts to use quantum theory to describe it have so far failed. Other theories, including modifications of gravity, have gained little acceptance.
"It could be none of the above," Coles says. But "we wouldn't be on the trail of this 'none-of-the-above' if it hadn't been for these experiments". ■
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